The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | CheckMate 649: 1L nivo + chemotherapy improves OS
Mohamed E. Salem, MD, Levine Cancer Institute, Charlotte, NC, talks on the findings of CheckMate 649 (NCT02872116), a Phase III study of first-line (1L) nivolumab (nivo) plus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. In this expanded efficacy and safety update, the addition of nivolumab to chemotherapy demonstrated improved overall survival and progression-free survival benefit in all randomized patients, as well as an acceptable safety profile and maintained tolerability. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
